Good Lifestyle

Type 2 diabetes treatment Ozempic has become the biggest name in the weight loss medication market, but it is far from the only option available at this stage. Novo Nordisk, which manufactures Ozempic, has a prescribed option for weight loss (Wegovy), just like other brands like Eli Lilly, which makes Zepbound . Today, the manufacturer of Altimmune drugs is on the scene, announcing positive results of a study of his new medication, the PEMVIDUDUDID. After 48 weeks of treatment, a third of patients taking PEMVIDUDITIDE have lost 20% or more of their body weight.

In relation: A whole new medication reverses obesity without real side effects, say the researchers .

The momentum test of the pemvidudutide included 391 obesity participants (or who were overweight) and at least a comorbidity, and without diabetes, by a November 30 press release from Altimmune. At the start of the study, the subjects were an average age of 50 and an average weight of 229 pounds (104 kilograms). Seventy-five percent of the participants were women.

Participants were randomly assigned to receive a dose of pemvidudutide, or a placebo, which they took once a week for 48 weeks for 48 weeks for 48 weeks of 1.2 milligrams, 1.8 milligram. Those who received the dose of 2.4 milligrams have passed in a four -week titration period (from a lower level and operating up to the dose of 2.4 milligrams).

At the 48 -week mark, those who receive the dose of 2.4 milligrams lost 15.6% of their body weight, while those of the 1.8 milligram dose lost 11.2%, and those of the dose of 1.2 milligrams lost 10.3%. Participants who took the placebo lost only 2.2% of their body weight.

The press release noted that more than 50% of participants lost at least 15% of their body weight - and even more, 30% of people in the highest dose lost 20% or more of their body weight. AE0FCC31AE342FD3A1346EBB1F342FCB

"To put these results in the context, the average weight loss of 15.6% observed with the dose of 2.4 mg was associated with an average weight loss of 32.2 lb at 48 weeks", " VIIN K. GARG , Said PhD, president and chief executive officer of Altimmune, in the press release. "The impact of this level of weight loss on patients can be significant. For example, 48% of subjects on the dose of 2.4 mg with basic obesity had no obesity at the end of the 48 -week test. "

Study participants also experienced additional health benefits, including reductions in "bad" cholesterol (LDL cholesterol), triglycerides (which can increase your risk of heart disease at high levels) and blood pressure.

"We believe that the extent of weight loss, robust discounts of triglycerides, LDL cholesterol and blood pressure, as well as the safety profile observed in this test, could potentially differentiate the PEMVIDUDITIDE from other therapies based on 'Incredine, "Garg said in the press release.

Incretins are a potential target for the treatment of obesity, because incredine system consists of hormones that seem to contribute to weight loss.

In relation: The new drug has people who lose 19% of body weight, according to research - and it is not Ozempic .

However, certain undesirable events (IS) were reported during the study, with the most common nausea and vomiting, ranging from light to moderate gravity. No special interest or major unwanted cardiac events was noted, but a serious adverse event (SAE) was reported by a patient taking the dose of 2.4 milligrams, which was a case of vomiting.

The AES caused 6.2% of those who took a placebo to interrupt treatment, and 5.1%, 19.2% and 19.6% of those who take doses of 1.2, 1.8 and respectively respectively 2.4 milligrams to stop treatment. Some also abandoned the study, most judgments due to IS in treatment groups occurring in the first 16 weeks of treatment. The press release also noted that more patients who had received PEMVIDUDITIDE finished the trial than those who received a placebo (74% against 61.9%, respectively).

According to the press release, the PEMVIDUDITIDE is a peptide 1 glucagon based on peptide (GLP-1) / agonist of the Glucagon duel receptor. When the GLP-1 and Glucagon receptors are activated, it imitates the effects of food and exercise, noted release, while GLP-1 also removes appetite. It is in development for the treatment of obesity as well as liver diseases Steatohepatitis associated with metabolic dysfunction (puree), formerly known as non -alcoholic steatohepatitis (Nash). In October, the US Food and Drug Administration (FDA) granted an Altimune rapid track designation for the PEMVIDUDITIDE for puree treatment .

"If it is approved, we believe that the PEMVIDUDUDID could offer an important option for obesity patients, including those with risk factors for cardiovascular disease," Garg said in the press release.

In relation: For more information, register for our daily newsletter .

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.